Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms

Fig. 4

The relationship between CADM3 and the clinical characteristics of BC patients in TCGA (A-E): (A) ER status, (B) PR status, (C) HER-2 status, (D) age, (E) PAM50 subtypes. The association between CADM3 and clinical features in clinical samples (F-I): (F) ER status, (G) PR status, (H) age, (I) PAM50 subtypes. Wilcoxon rank sum test was used for statistical analysis of ER, PR, HER2 status and age group. Kruskal-Wallis Test and Dunn’s test were used for the PAM50 group

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us